Tumor endothelial markers as a target in cancer

Domenico Ribatti, Girolamo Ranieri, Antonio Basile, Amalia Azzariti, Angelo Paradiso, Angelo Vacca

Research output: Contribution to journalArticle

Abstract

Introduction: Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help to target endothelium and to identify potential predictive factors of response to anti-angiogenic therapies. Numerous surrogates, angiogenic and endothelium markers have emerged from recent pre-clinical studies, including physiological and soluble molecules in plasma and from platelets, circulating cells, tumor tissue factors and imaging markers. However, no wholly validated biomarkers currently exist to predict the success or the failure of the anti-angiogenic therapy of cancer. Therefore, the research of suitable and validate biomarkers is currently ongoing. Areas covered: This review provides an overview of the status of our knowledge concerning tumor endothelial markers, therapeutics targeting, possible resistance mechanisms and predictive value of these biomarkers and discuss future strategies to use and identify them in the anti-angiogenic therapy. Expert opinion: Anti-angiogenesis is a milestone to improve the treatment of several types of cancer and predictive biomarkers for a response to anti-endothelium therapy are one of the most important challenges for anti-angiogenesis research.

Original languageEnglish
Pages (from-to)1215-1225
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Biomarkers
Tumor Biomarkers
Tumors
Neoplasms
Endothelium
Thromboplastin
Therapeutics
Platelets
Circulating Neoplastic Cells
Plasmas
Imaging techniques
Expert Testimony
Molecules
Research
Blood Platelets

Keywords

  • Cancer
  • Endothelium
  • Markers
  • Therapy
  • Tumor growth

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Tumor endothelial markers as a target in cancer. / Ribatti, Domenico; Ranieri, Girolamo; Basile, Antonio; Azzariti, Amalia; Paradiso, Angelo; Vacca, Angelo.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. 12, 12.2012, p. 1215-1225.

Research output: Contribution to journalArticle

Ribatti, Domenico ; Ranieri, Girolamo ; Basile, Antonio ; Azzariti, Amalia ; Paradiso, Angelo ; Vacca, Angelo. / Tumor endothelial markers as a target in cancer. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. 12. pp. 1215-1225.
@article{426a3438b09c419d9e3fde33ad6f305f,
title = "Tumor endothelial markers as a target in cancer",
abstract = "Introduction: Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help to target endothelium and to identify potential predictive factors of response to anti-angiogenic therapies. Numerous surrogates, angiogenic and endothelium markers have emerged from recent pre-clinical studies, including physiological and soluble molecules in plasma and from platelets, circulating cells, tumor tissue factors and imaging markers. However, no wholly validated biomarkers currently exist to predict the success or the failure of the anti-angiogenic therapy of cancer. Therefore, the research of suitable and validate biomarkers is currently ongoing. Areas covered: This review provides an overview of the status of our knowledge concerning tumor endothelial markers, therapeutics targeting, possible resistance mechanisms and predictive value of these biomarkers and discuss future strategies to use and identify them in the anti-angiogenic therapy. Expert opinion: Anti-angiogenesis is a milestone to improve the treatment of several types of cancer and predictive biomarkers for a response to anti-endothelium therapy are one of the most important challenges for anti-angiogenesis research.",
keywords = "Cancer, Endothelium, Markers, Therapy, Tumor growth",
author = "Domenico Ribatti and Girolamo Ranieri and Antonio Basile and Amalia Azzariti and Angelo Paradiso and Angelo Vacca",
year = "2012",
month = "12",
doi = "10.1517/14728222.2012.725047",
language = "English",
volume = "16",
pages = "1215--1225",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Tumor endothelial markers as a target in cancer

AU - Ribatti, Domenico

AU - Ranieri, Girolamo

AU - Basile, Antonio

AU - Azzariti, Amalia

AU - Paradiso, Angelo

AU - Vacca, Angelo

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help to target endothelium and to identify potential predictive factors of response to anti-angiogenic therapies. Numerous surrogates, angiogenic and endothelium markers have emerged from recent pre-clinical studies, including physiological and soluble molecules in plasma and from platelets, circulating cells, tumor tissue factors and imaging markers. However, no wholly validated biomarkers currently exist to predict the success or the failure of the anti-angiogenic therapy of cancer. Therefore, the research of suitable and validate biomarkers is currently ongoing. Areas covered: This review provides an overview of the status of our knowledge concerning tumor endothelial markers, therapeutics targeting, possible resistance mechanisms and predictive value of these biomarkers and discuss future strategies to use and identify them in the anti-angiogenic therapy. Expert opinion: Anti-angiogenesis is a milestone to improve the treatment of several types of cancer and predictive biomarkers for a response to anti-endothelium therapy are one of the most important challenges for anti-angiogenesis research.

AB - Introduction: Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help to target endothelium and to identify potential predictive factors of response to anti-angiogenic therapies. Numerous surrogates, angiogenic and endothelium markers have emerged from recent pre-clinical studies, including physiological and soluble molecules in plasma and from platelets, circulating cells, tumor tissue factors and imaging markers. However, no wholly validated biomarkers currently exist to predict the success or the failure of the anti-angiogenic therapy of cancer. Therefore, the research of suitable and validate biomarkers is currently ongoing. Areas covered: This review provides an overview of the status of our knowledge concerning tumor endothelial markers, therapeutics targeting, possible resistance mechanisms and predictive value of these biomarkers and discuss future strategies to use and identify them in the anti-angiogenic therapy. Expert opinion: Anti-angiogenesis is a milestone to improve the treatment of several types of cancer and predictive biomarkers for a response to anti-endothelium therapy are one of the most important challenges for anti-angiogenesis research.

KW - Cancer

KW - Endothelium

KW - Markers

KW - Therapy

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=84869457543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869457543&partnerID=8YFLogxK

U2 - 10.1517/14728222.2012.725047

DO - 10.1517/14728222.2012.725047

M3 - Article

C2 - 22978444

AN - SCOPUS:84869457543

VL - 16

SP - 1215

EP - 1225

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 12

ER -